| Metric | Value (₹ Cr) | vs Q3 FY25 |
|---|---|---|
| Revenue | 6.7K | 4.8% |
| Total Income | 7.0K | 3.8% |
| Expenditure | 5.5K | 2.5% |
| PBT | 1.5K | 21.5% |
| Net Profit | 1.2K | 22.9% |
| OPM | 22.85% | 3.06pp |
| NPM | 17.30% | 4.41pp |
| EPS | 15.13 | 22.2% |
Cipla Ltd Reports 8% Revenue Growth YoY in Q4 FY25, Driven by Operational Efficiencies
13 May 2025 · 13 May 2025, 06:56 pm
Summary
Cipla Limited, a leading global pharmaceutical company, announced its audited consolidated financial results for the quarter ended March 31, 2025. The company recorded a revenue growth of 8% YoY, driven by operational efficiencies. The One-India business grew at a healthy 7% YoY, with key therapies in Branded Prescription business outpacing the market growth. The US business posted an all-time high annual revenue of $ 934 Mn. One Africa recorded a solid growth of 12% YoY in USD terms, and Emerging Markets and Europe delivered a substantial revenue growth of 15% YoY in USD terms.
Key Highlights
- 1
Revenue growth of 8% YoY with EBITDA margin of 25.9%
- 2
One-India business grew at a healthy 7% YoY
- 3
US business posted an all-time high annual revenue of $ 934 Mn
- 4
One Africa recorded a solid growth of 12% YoY in USD terms
- 5
Emerging Markets and Europe delivered a substantial revenue growth of 15% YoY in USD terms
- 6
One-India Business grew at a healthy 8% YoY during the quarter
- 7
Branded Prescription business continued to outpace the market growth in key chronic therapies
- 8
US business posted an all-time high annual revenue of $ 934 Mn
- 9
One Africa delivered a robust quarterly growth of 15% YoY in USD terms and an annual growth of 12% YoY in USD terms
- 10
Emerging Markets and Europe delivered a strong quarterly growth of 16% YoY in USD terms and yearly growth of 15% YoY in USD terms
Management Comments
Umang Vohra
I am pleased to share that we continue to make considerable progress across our focused markets. In FY25, we recorded a revenue growth of 8% over last year with the EBITDA margin of 25.9%, driven by mix and other operational efficiencies. Our One-India business grew at a healthy 7% YoY. Key therapies in Branded Prescription business continued to outpace the market growth, Trade Generics business growth trajectory is back on track and Anchor brands of Consumer Health Business maintained leadership position. With a positive traction in our differentiated assets, the US business posted an all-time high annual revenue of $ 934 Mn. In One Africa, we recorded a solid growth of 12% YoY in USD terms, powered by firm performance across key markets. Emerging Markets and Europe delivered a substantial revenue growth of 15% YoY on the back of deep market focus strategy. Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front.
Informational and educational content only. Not investment advice.